Neumora Reveals Mid-Stage Data For Fully Funded, Phase III-Ready Depression Drug
Private Biotech Has Raised $650m To Date
Neumora's navacaprant aims to treat anhedonia, an inability to experience pleasure or joy, in depression patients • Source: Shutterstock 
